<SEC-DOCUMENT>0001683168-18-000092.txt : 20180110
<SEC-HEADER>0001683168-18-000092.hdr.sgml : 20180110
<ACCEPTANCE-DATETIME>20180110090510
ACCESSION NUMBER:		0001683168-18-000092
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180104
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180110
DATE AS OF CHANGE:		20180110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		18520418

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)
January 4, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">001-37487</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 68%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8910 University Center Lane, Suite 660</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California</P></TD>
    <TD STYLE="width: 32%; text-align: center; font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">92122</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Indicate by checkmark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Emerging growth company.&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Form 8-K and other reports filed by Registrant from time
to time with the Securities and Exchange Commission (collectively, the &quot;Filings&quot;) contain or may contain forward-looking
statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well
as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate,&rdquo; &quot;believe,&quot;
&quot;estimate,&quot; &quot;expect,&quot; &quot;future,&quot; &quot;intend,&quot; &quot;plan&quot; or the negative of these terms
and similar expressions as they relate to Registrant or Registrant's management identify forward-looking statements. Such statements
reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other
factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired
by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although Registrant believes that the expectations reflected
in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or
achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend
to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 5.02 Appointment of a Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective January 4, 2018, Sabrina Martucci Johnson joined the
Board of Directors of Aethlon Medical, Inc. (the &ldquo;Company&rdquo;) and was appointed to its Audit Committee. Ms. Johnson meets
the requirements to serve as an independent director of the Company under the applicable Nasdaq Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ms. Johnson founded
Dar&eacute; Science Operations, Inc. in 2015 and has served as President, CEO and a member of the Board of Directors since its
inception. This company was acquired through a reverse merger by Cerulean Pharma Inc. on July 19, 2017, and Ms. Johnson assumed
the roles of President, CEO and a member of the Board of Directors of the renamed company, Dar&eacute; Bioscience, Inc. &nbsp;Prior
to founding Dar&eacute;, Ms. Johnson was President of WomanCare Global Trading, a specialty pharmaceutical company in female reproductive
healthcare with commercial product distribution in over 100 countries, from October of 2014 to May of 2015. Before serving as President
of WomanCare Global Trading, Ms. Johnson provided financial consulting services to the WomanCare Global family of companies, including
the for-profit Trading division as well as the United Kingdom-based non-profit division, from November of 2012 to July of 2013,
when she joined full time as WomanCare&rsquo;s Chief Financial Officer and Chief Operating Officer until becoming President of
the Trading division. In addition, Ms. Johnson served as Chief Operating Officer and Chief Financial Officer of Cypress Bioscience,
Inc. until its sale in 2010. Ms. Johnson also held marketing and sales positions with Advanced Tissue Sciences and Clonetics Corporation.
She began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on
their recombinant factor VIII program.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ms. Johnson currently
serves on the YWCA of San Diego County Board of Directors as Past President, PPPSW Board of Directors, Athena San Diego Board of
Directors as Vice Chair, Tulane University School of Science &amp; Engineering Board of Advisors, University of California San
Diego (UCSD) Librarian&rsquo;s Advisory Board as Chair and Project Concern International Audit Committee. Ms. Johnson is also Immediate
Past Co-President of Women Give San Diego, which funds non-profit organizations serving women and girls in San Diego.&#8203; She
holds an MIM from the American Graduate School of International Management (Thunderbird) with honors, a MSc. in Biochemical Engineering
from the University of London, University College London, and a BSc. in Biomedical Engineering from Tulane University, where she
graduated magna cum laude.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><B>ITEM 9.01
Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit 99.1</FONT></TD>
    <TD STYLE="width: 81%"><A HREF="aethlon_8k-ex9901.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release, dated January 10, 2018</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 57%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AETHLON MEDICAL, INC.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;<U>/s/ James B. Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;James B. Frakes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: January 10, 2018</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sabrina Martucci Johnson Joins Aethlon
Medical&rsquo;s Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAN DIEGO, CA, January 10, 2018 -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced
the appointment of Sabrina Martucci Johnson to its Board of Directors and to its Audit Committee. Ms. Johnson qualifies as an independent
director under the Nasdaq Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&ldquo;We are very pleased
to have Sabrina join the Aethlon team,&rdquo; stated Aethlon Medical founder and CEO, Jim Joyce. &ldquo;With the recent &ldquo;Breakthrough
Device&rdquo; designation of our Hemopurifer, Sabrina&rsquo;s appointment reflects our focus to build a Board of Directors with
relevant experience in transitioning clinical-stage therapies to the marketplace.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&quot;I am pleased to be joining the board and assisting in
the strategy to bring the Aethlon Hemopurifier&reg; therapeutic device to market,&rdquo; stated Sabrina Martucci Johnson. &ldquo;It
is an honor to work on a program that has the opportunity to address life-threatening viral infections that are not addressed with
approved therapies.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sabrina Martucci Johnson is the Founder and CEO of DAR&Eacute;
Bioscience (NASDAQ:DARE),&nbsp;a healthcare company committed to the development and commercialization of innovative products in
women&rsquo;s reproductive health. &nbsp;Prior to founding DAR&Eacute;, Sabrina was President of WomanCare Global Trading,&nbsp;a
global provider of women&rsquo;s health products, and CFO/CAO of the California Institute for Biomedical Research.&nbsp; She served
as COO and CFO of Cypress Bioscience, Inc. (NASDAQ:CYPB), the developer of the PROSORBA column, where she launched and secured
a global partner for that apheresis product until its sale for $250 million in 2010. She also held sales and marketing positions
with Advanced Tissue Sciences and Clonetics Corporation.&nbsp; She began her career in the biotechnology industry as a research
scientist with Baxter Healthcare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the community Sabrina serves on the board of organizations
that advance the economic well-being and health of women and girls and promote education.&nbsp;&nbsp;She serves on the YWCA of
San Diego County Board of Directors as immediate past-president, Clearity Foundation Board of Directors, Athena Board of Directors
as Co-Chair, Tulane University School of Science &amp; Engineering Board of Advisors, University California San Diego Librarian&rsquo;s
Advisory Board, Project Concern International Audit Committee, and Sabrina is the immediate past co-president of Women Give San
Diego.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sabrina has a Master of International Management with honors
from the American Graduate School of International Management (Thunderbird); a MSc. in Biochemical Engineering from the University
of London, University College London; and a BSc. in Biomedical Engineering from Tulane University, magna cum laude.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical is focused on addressing
unmet needs in global health and biodefense. The Aethlon Hemopurifier&reg; is a first-in-class therapeutic device designed to address
life-threatening viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier&reg; to
a Breakthrough Device related to the treatment of life-threatening viruses that are not addressed with approved therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In collaboration with leading government
and non-government research institutes, Aethlon has validated the ability of the Hemopurifier&reg; to capture a broad-spectrum
of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses. Based on its use to treat Ebola virus, the
Hemopurifier&reg; was named a &quot;Top 25 Invention&quot; and one of the &quot;Eleven Most Remarkable Advances in Healthcare,&quot;
by TIME Magazine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon is also investigating the potential
therapeutic use of the Hemopurifier&reg; to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression
and the spread of metastasis in cancer patients. Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which
is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's
disease (AD) and Chronic Traumatic Encephalopathy (CTE). Additional information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com. You can also connect with us on Twitter, LinkedIn, Facebook and Google+.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934
that involve risks and uncertainties. Statements containing words such as &quot;may,&quot; &quot;believe,&quot; &quot;anticipate,&quot;
&quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;project,&quot; &quot;will,&quot; &quot;projections,&quot; &quot;estimate,&quot;
or similar expressions constitute forward-looking statements. Forward-looking statement includes statements relating to the public
offering and the satisfaction of closing conditions relating to the public offering, as well as general economic and market factors.
Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from
the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation,
the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the
Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation
of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital
when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its
products either internally or through outside companies, the impact of government regulations, patent protection on the Company's
proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability
exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks
and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from
those anticipated in forward-looking statements can be found under the caption &quot;Risk Factors&quot; in the Company's Annual
Report on Form 10-K for the year ended&nbsp;March 31, 2017, and in the Company's other filings with the Securities and Exchange
Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information
to reflect future events or circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">858-459-7800 extension 3300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Marco</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CORE IR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">516 222 2560</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">johnm@coreir.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !: / # 2(  A$! Q$!_\0
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MW:<?]6^J_P!DR_W*J@^UC89:]?W]F^-W25:;LE"4+=80%AS=^R2,@A0Y9!Y
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M7U8/;#U+&5INVZ1A*$B\3I;;QCM^LM"$Y"<@<BI1  ZX-9VU^QKTUV5$V9T
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7V^/OK/P*4JD22;E60 !8)2E*^+ZO_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
